Monica Mead

42PUBLICATIONS

225CO-AUTHORS

Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (42)

Sort by Publication Date:

|Jun 03, 2026

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

|Apr 16, 2026

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

|Mar 10, 2026

Current treatment algorithm: diffuse large B cell lymphoma.

Stephen M Ansell, Grzegorz S Nowakowski

|Jan 07, 2026

Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.

Domitilla Baccon, Suheil Albert Atallah-Yunes, Paul J Hampel

|Oct 28, 2025

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Mouhamad Khouja, Britta Kehden, Derek Blair

|Oct 27, 2025

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Edward R Scheffer Cliff, Guido D Pelaez, Fei Wan

Pageof 7

Frequent Collaborators

18 joint publications

James R Cerhan

17 joint publications

Stephen M Ansell

16 joint publications

Matthew Maurer

15 joint publications

Thomas Witzig

15 joint publications

Yucai Wang

12 joint publications

Thomas M Habermann

Andrew L Feldman

Rebecca L King

Anne J Novak

Susan Slager

Frequent Collaborators

18 joint publications

James R Cerhan

17 joint publications

Stephen M Ansell

16 joint publications

Matthew Maurer

15 joint publications

Thomas Witzig